Exosomes in lung cancer liquid biopsies: Two sides of the same coin?

The absence of suitable diagnostic, prognostic and predictive biomarkers for non-small cell lung cancer (NSCLC) and the limited efficacy of the available treatments are responsible of the low survival rates of this disease. Conventional chemotherapy, in combination with radiotherapy, has improved outcomes, but a significant proportion of NSCLC patients do not respond to these treatments [1]. The discovery of new molecular targets and drugs, as tyrosine-kinase inhibitors (TKIs) have led to the development of different generations of targeted therapies ameliorating clinical outcomes of the disease. But however, still nowadays there are no definitive treatments for NSCLC and the research of new non-invasive early diagnostic and prognostic biomarkers is mandatory [2]. In this field, liquid biopsies, which include tumor components as circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) and exosomes, could be the long awaited response to this tricky task [3].

Exosomes, one of the lesser-known liquid biopsies components, are cell-derived nanovesicles (30–100 nm of diameter) firstly described studying reticulocyte differentiation [4]. Exosomes are formed by the inward budding of multivesicular bodies (MVB), component of the endocytic pathway [5]. Exosomes are released from different types of cells both under physiological and pathological conditions and, interestingly, have been well detected in several body fluids, such as peripheral blood, urine, pleural effusion, amniotic fluid, saliva, breast-milk and cerebrospinal fluid [3,6]. They function as messenger particles, playing a role in cell-to-cell communication and to deliver proteins, lipids, miRNAs and mRNAs with biological activity in the target cells [3]. Now it is well known that these vesicles have pleiotropic functions in remodeling the tumor microenvironment, promoting immune escape and in tumor progression [7].

In the last years, the molecular profiling of these nanovesicles in the plasma of patients with NSCLC, offered the opportunity to delineate better the characteristics of the disease. Exosomes released from NSCLC patients contain proteins related to tumor growth and progression, such as EGFR, claudins, K-ras and inducers of matrix metalloproteinase synthesis like EMMPRIN [8]. Similarly to these findings, in other cancer types several exosomal proteins have been described with diagnostic and prognostic features, such as MIA and S100B in melanoma and Glypican-1 in early pancreatic cancer [9,10]. So, these features might be exploited as a source of specific biomarkers because they reflect the pathological features of the disorder. Jakobsen et al. demonstrated the potential diagnostic properties of exosomal proteins in advanced NSCLC. Exosomes isolated from plasma of 109 NSCLC patients (stage IIIa – IV) and 110 healthy controls were analyzed with an extracellular vesicle array that phenotyped the exosomes directly from the plasma samples using 37 antibodies against lung cancer-related proteins, initiating the way to generate minimally invasive tools to detect exosome-derived biomarkers [11]. In this context, plasma from 431 lung cancer patients were analyzed in order to identify potential diagnosis proteins and demonstrating a protein profile associated to adenocarcinoma [12]. Other exosome’s features suitable to be biomarkers have been also demonstrated in studies of other body fluids, such as urine. For example, Li et al., in NSCLC patients demonstrated a positive correlation rate of 65% between the presence of leucine-rich α-2-glycoprotein (LRG1) measured in primary tumor and in urinary exosomes. This study indicates that LRG1 in urinary exosomes might be derived from primary tumor tissue and, then, could be suitable as a non-invasive diagnostic biomarker of NSCLC in this selected population [13]. In preclinical analysis with NSCLC cell lines, a proteomic profiling was performed in exosomes identifying a total of 721 proteins. Among these, several proteins such as EGFR, SRC and GRB2, were found really enriched, suggesting then their potential prognostic biomarker role in NSCLC patients [14]. Recently, it has been described for the first time the translocation of ALK-EML4 inside exosomes from NSCLC patients, broadening exosome characterization as a powerful tool for molecular identification [15].

Exosomes have been described also as delivery systems, specifically, exosomes derived from dendritic cells (DEX) have been studied as possible immunotherapy components since they carry major histocompatibility complex (MHC) molecules and are able to present antigens to immune cells as CD4 and CD8 T lymphocytes [16]. A phase I and a phase II trial have been performed with DEX, concluding in both cases the safety of the administration of DEX and DEX carrying IL-15Ra and NKG2D and the ability of DEX to activate both innate and adaptive immune systems [17,18].

In addition to their effects on the primary tumor microenvironment, exosomes also play a strong role, together with chemokines, in the establishment of the pre-metastatic niche. In SCID mice it has been demonstrated that there is a lung pre-metastatic niche formation mediated also by CD105-positive exosomes through an upregulation of proteins such as VEGFR1, MMP2 and MMP9 [19]. In other preclinical studies, exosomes were also described as potential drug resistance vectors. Xiao et al. demonstrated in vitro that exosomes released by A549 cells were involved in the regulation of the sensitivity of these cells to DNA-damaging Platinum (DDP). Furthermore, exosomes released by A549 cells during DDP exposure decreased the sensitivity of other untreated A549 cells to DDP, which may be mediated by exosome-mediated proteins, miRNAs and mRNAs cell exchange [20].

The characterization of tissueal miRNA profiles in NSCLC patient’s [21,22] prompts the idea that exosomal miRNA profile could also mirror the tumoral tissue profile, and serve as a specific liquid biopsy biomarker [23]. In this regards, Rabinowits et al., for the first time, demonstrated that in lung adenocarcinoma patients there is a similarity between exosomal miRNAs and tumor-derived miRNAs profiles, suggesting that 12 specific exosomal miRNAs

http://dx.doi.org/10.1016/j.lungcan.2016.11.014
0169-5002/© 2016 Elsevier Ireland Ltd. All rights reserved.


Christian Rolfo∗ Marco Giolimbardaro Pablo Reclusa Rafael Sirera Marc Peeters

Phase I – Early Clinical Trials Unit, Oncology Department, Antwerp University Hospital & Center for Oncological Research (CORE) Antwerp University, Antwerp, Belgium

∗Corresponding author at: Head of Phase I – Early Clinical Trials Unit, Oncology Department Antwerp University Hospital, Wilrijkstraat 10, 2650 Edegem, Belgium.

E-mail address: christian.rolfo@ua.be (C. Rolfo)

Christian Rolfo∗ Marco Giolimbardaro Pablo Reclusa Rafael Sirera Marc Peeters

Phase I – Early Clinical Trials Unit, Oncology Department, Antwerp University Hospital & Center for Oncological Research (CORE) Antwerp University, Antwerp, Belgium

∗Corresponding author at: Head of Phase I – Early Clinical Trials Unit, Oncology Department Antwerp University Hospital, Wilrijkstraat 10, 2650 Edegem, Belgium.

E-mail address: christian.rolfo@ua.be (C. Rolfo)

26 July 2016
10 November 2016
17 November 2016